Source URL: https://medicines.health.europa.eu/veterinary/en/600000083079

PENETHAONE Powder and solvent for suspension for injection for cattle

Authorised

Penethamate hydriodide

Product identification

Medicine name:

PENETHAONE Powder and solvent for suspension for injection for cattle Penethaone vet 236,3 mg/ml Pulver och vätska till injektionsvätska, suspension

Active substance:

Penethamate hydriodide

Target species:

Cattle (lactating cow)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Penethamate hydriodide 236.30 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Powder and solvent for suspension for injection

Withdrawal period by route of administration: Intramuscular use:

Cattle (lactating cow)

- Meat and offal. 4 day
- Milk. no withdrawal period

Meat and offal: 4 days; Milk: 2,5 days/60 hours.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CE90

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Sweden

Available in:

Sweden

Package description:

box containing $10 \times 10,000,000$ IU powder vial and 10×36 ml solvent vial box containing $5 \times 10,000,000$ IU powder vial and 5×36 ml solvent vial box containing $1 \times 10,000,000$ IU powder vial and 1×36 ml solvent vial box containing $10 \times 5,000,000$ IU powder vial and 10×18 ml solvent vial box containing $5 \times 5,000,000$ IU powder vial and 5×18 ml solvent vial box containing $1 \times 5,000,000$ IU powder vial and 1×18 ml solvent vial

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Divasa Farmavic S.A.

Marketing authorisation date:

3/09/2015

Manufacturing sites for batch release:

DIVASA-FARMAVIC, S.A.

Responsible authority:

Swedish Medical Products Agency

Authorisation number:

51180

Date of authorisation status change:

3/09/2015

Reference member state:

Spain

Procedure number:

ES/V/0226/001

Concerned member states:

Austria Belgium Bulgaria Czechia Denmark France Germany Greece Hungary Iceland Ireland Italy Lithuania Netherlands Norway Poland Portugal Romania Slovakia Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

English (PDF)

Published on: 26/12/2023

Download